Topics in Anti-Cancer Research 7

Cover
 Title
 Biblography
 End User License Agreement
 Contents
 Preface
 Introduction
 List of Contributors
 The Role of ncRNAs in Human Cancer and its Related Patents
 María I. Navarro-Mendoza1, Carlos Pérez-Arques1, Laura Murcia1, Alfonso F. López-Martínez2 and Francisco E. Nicolás1,*
 1. INTRODUCTION
 2. SMALL NCRNAS: MIRNAS, PIRNAS, TIRNAS, SNORNAS AND PARNAS
 2.1. miRNAs
 2.2. piRNAs
 2.3. tiRNAs
 2.4. snoRNAs
 2.5. Small Promoter Associated RNAs
 2.6. Other Small ncRNAs
 3. LONG NCRNAS: LINCRNAS, T-UCRS, CERNAS AND OTHER LNCRNAS
 3.1. LincRNAs
 3.2. T-UCRs
 3.3. CeRNAs 3.4. Other lncRNAsCURRENT & FUTURE DEVELOPMENTS
 CONSENT FOR PUBLICATION
 CONFLICT OF INTEREST
 ACKNOWLEDGEMENTS
 DISCLOSURE
 REFERENCES
 Taxol To Nanotaxol: A Journey Towards Enhanced Drug Delivery
 Tanvi Kaku1, Aiswarya Dash2 and Biswa P. Chatterji2,*
 1. INTRODUCTION
 1.1. Methods for Preparation of Paclitaxel Nanoparticles
 1.1.1. CN1463969A
 1.1.2. CN101829061A
 1.2. Human Serum Albumin (HSA) Associated and Other Protein Associated and Functionalized Taxol® or Paclitaxel Nanoparticles as Drug Delivery Agents
 1.2.1. US6506405B1
 1.2.2. US8268348B2 and US20100112077A1 1.2.3. WO1994018954A11.2.4. US20040092577A1
 1.2.5. US20090004118
 1.2.6. US20090226393
 1.2.7. US20100015051
 1.2.8. US20100303723
 1.2.9. WO2007034479
 1.3. Micelles, Emulsions and Liposomes as Drug Delivery Carriers for Paclitaxel
 1.3.1. US20150366806
 1.3.2. WO2009070761
 1.3.3. EP2494956 and EP2494957
 1.3.4. WO1994007484
 1.3.5. WO1996002247
 1.3.6. CN102772368A
 1.3.7. US5424073
 1.3.8. KR101612194
 1.3.9. US8663599B1
 1.4. Carbon Nanoparticles as Drug Delivery Agents for Cancer Chemotherapy
 1.4.1. EP3063091
 1.4.2. US20090087493
 1.4.3. KR20180016231
 1.4.4. CN104998261 1.4.5. WO20140153341.5. Nanodevices for Paclitaxel Delivery to Cancer Cells
 1.5.1. US20100215724
 1.5.2. US20100303716
 DISCUSSION
 CURRENT & FUTURE DEVELOPMENTS
 CONSENT FOR PUBLICATION
 CONFLICT OF INTEREST
 ACKNOWLEDGEMENTS
 REFERENCES
 Advanced Therapy in Cancer: Stimuli-Responsive Nanocarriers for On-Demand Drug Delivery
 Azadeh Haeri*, Fatemeh Mehryab and Hamid R. Moghimi
 1. INTRODUCTION
 2. STIMULI-RESPONSIVE NANOCARRIERS
 3. EXTERNAL STIMULI-RESPONSIVE DRUG DELIVERY
 3.1. Temperature-Responsive Nanocarriers
 3.2. Magnetic Field-Responsive Nanocarriers 3.3. Photo-Responsive Nanocarriers3.4. Ultrasound-Responsive Nanocarriers
 4. INTERNAL STIMULI-RESPONSIVE DRUG DELIVERY
 4.1. pH-Responsive Nanocarriers
 4.2. Enzyme-Responsive Nanocarriers
 4.3. Redox-Responsive Nanocarriers
 5. OTHER STIMULI-RESPONSIVE NANOCARRIERS
 CONCLUSION
 CURRENT & FUTURE DEVELOPMENTS
 CONSENT FOR PUBLICATION
 CONFLICT OF INTEREST
 ACKNOWLEDGEMENTS
 REFERENCES
 The Regulation and the Function of Autophagy in the Development and Behavior of Esophageal Cancers
 Erdem Ayik* and Gulsum O. Elpek
 1. INTRODUCTION
 2. GENERAL ASPECTS OF AUTOPHAGY
 3. AUTOPHAGY IN CANCER